Aleksandra Butrym
Wrocław Medical University
97 Papers
233 Citations
Aleksandra Butrym is an academic researcher from Wrocław Medical University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 15, co-authored 76 publications. Previous affiliations of Aleksandra Butrym include University of Wrocław.
Chat about Author
Papers
Pb2010: first-line treatment patterns and outcomes among patients with newly diagnosed myelodysplastic syndromes: a global, retrospective observational cohort study
Amer M. Zeidan,Aleksandra Butrym,Aylin Yucel,Gaurav A. Deshpande,Min Che,T. Gu,Hong Xiao,Dimana O. Miteva,J. Nadal,Kim Le,Argiris Symeonidis +10 more
TL;DR: This global, retrospective study of 421 patients with newly diagnosed lower-risk myelodysplastic syndromes (MDS) found that most received erythropoiesis-stimulating agents (ESAs) as first-line treatment, with limited clinically meaningful hemoglobin improvement and frequent disease progression.
Genetic variation of the gene coding for microRNA-204 (miR-204) is a risk factor in acute myeloid leukaemia
Aleksandra Butrym,Piotr Łacina,Kazimierz Kuliczkowski,Katarzyna Bogunia-Kubik,Katarzyna Bogunia-Kubik,Grzegorz Mazur +5 more
TL;DR: The results show that polymorphism in miR-204 flanking region may constitute a risk and prognostic factor in AML.
Potential of high‐titre IgA convalescent plasma to improve survival and symptoms in COVID‐19 patients
Agnieszka Kus,Szymon Wieczorek,Jarosław Dybko,Małgorzata Szymczyk-Nuzka,Aleksandra Butrym,Sebastian Makuch,Grzegorz Mazur,Siddarth Agrawal +7 more
TL;DR: Wroclaw Medical University, Wroclaw, Poland as discussed by the authors has a department of Hematology and Cellular Transplantation, Lower Silesian Oncology Center (LSOC).
Therapeutic adherence and assessment of satisfaction patients with multiple myeloma treated with immunomodulatory drugs in a "real-world" study: Experiences of the Polish Myeloma Group.
Grzegorz Charliński,Norbert Grzasko,Łukasz Bołkun,Waldemar Sawicki,Edyta Paczkowska,Agnieszka Druzd-Sitek,Lidia Usnarska-Zubkiewicz,Aleksandra Butrym,Elżbieta Wiater,Piotr Boguradzki,Bożena Katarzyna Budziszewska,Małgorzata Wojciechowska,Monika Mordak-Domagala,Artur Jurczyszyn +13 more
TL;DR: Patients with MM treated with IMiDs are highly adherent to treatment, and 95.5% of patients were satisfied with the information they received from the hematologist during treatment with IMs, indicating they adhere to the therapy rules.
POSTER: MDS-067 First-Line (1L) Treatment Patterns and Outcomes Among Patients With Newly Diagnosed Myelodysplastic Syndromes (MDS): A Global, Retrospective Observational Cohort Study
Argiris Symeonidis,Aylin Yucel,Gaurav A. Deshpande,Min Che,T. Gu,Hong Xiao,Dimana O. Miteva,J. Nadal,T. K. Le,Aleksandra Butrym +9 more